Volume 10 Issue 2
Mar.  2019
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2019  >  10(2): 112-121
Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for hypertension after solid organ transplantation in China (2019 edition)[J]. ORGAN TRANSPLANTATION, 2019, 10(2): 112-121. doi: 10.3969/j.issn.1674-7445.2019.02.002
Citation: Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for hypertension after solid organ transplantation in China (2019 edition)[J]. ORGAN TRANSPLANTATION, 2019, 10(2): 112-121. doi: 10.3969/j.issn.1674-7445.2019.02.002
shu

Diagnosis and treatment specification for hypertension after solid organ transplantation in China (2019 edition)

doi: 10.3969/j.issn.1674-7445.2019.02.002
  • Received Date: 2018-11-18
    Available Online: 2021-01-19
  • Publish Date: 2019-03-15
    Abstract
    • FullText(HTML)
  • loading
    • References(64)
  • [1]
    WEIR MR, BURGESS ED, COOPER JE, et al.Assessment and management of hypertension in transplant patients[J]. J Am Soc Nephrol, 2015, 26(6):1248-1260.DOI: 10.1681/ASN.2014080834.
    [2]
    JAMES PA, OPARIL S, CARTER BL, et al.2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the Eighth Joint National Committee (JNC 8)[J]. JAMA, 2014, 311(5):507-520.DOI: 10.1001/jama.2013.284427.
    [3]
    ZANCHETTI A, THOMOPOULOS C, PARATI G.Randomized controlled trials of blood pressure lowering in hypertension:a critical reappraisal[J]. Circ Res, 2015, 116(6):1058-1073.DOI: 10.1161/CIRCRESAHA.116.303641.
    [4]
    中华医学会器官移植分会, 中国医师协会器官移植医师分会.中国器官移植受者的高血压诊疗指南(2016版)[J].器官移植, 2016, 7(4):255-262.DOI: 10.3969/j.issn.1674-7445.2016.04.002.

    Branch of Organ Transplantation of Chinese Medical Association, Branch of Organ Transplant Physician of Chinese Medical Doctor Association.Guideline on hypertension management of recipients with organ transplantation in China (2016 edition)[J]. Organ Transplant, 2016, 7(4):255-262.DOI: 10.3969/j.issn.1674-7445.2016.04.002.
    [5]
    中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华心血管病杂志, 2011, 39(7):579-616.DOI: 10.3760/cma.j.issn.0253-3758.2011.07.002.

    Committee for the Revision of Guidelines on the Prevention and Treatment of Hypertension in China.2010 Chinese guidelines for the management of hypertension[J]. Chin J Cardiol, 2011, 39(7):579-616.DOI: 10.3760/cma.j.issn.0253-3758.2011.07.002.
    [6]
    FUSSNER LA, HEIMBACH JK, FAN C, et al.Cardiovascular disease after liver transplantation:when, what, and who is at risk[J]. Liver Transpl, 2015, 21(7):889-896.DOI: 10.1002/lt.24137.
    [7]
    MANGRAY M, VELLA JP.Hypertension after kidney transplant[J]. Am J Kidney Dis, 2011, 57(2):331-341.DOI: 10.1053/j.ajkd.2010.10.048.
    [8]
    HUSAIN-SYED F, MCCULLOUGH PA, BIRK HW, et al.Cardio-pulmonary-renal interactions:a multidisciplinary approach[J]. J Am Coll Cardiol, 2015, 65(22):2433-2448.DOI: 10.1016/j.jacc.2015.04.024.
    [9]
    KITTLESON MM, KOBASHIGAWA JA.Long-term care of the heart transplant recipient[J]. Curr Opin Organ Transplant, 2014, 19(5):515-524.DOI: 10.1097/MOT.0000000000000117.
    [10]
    WEINER DE, CARPENTER MA, LEVEY AS, et al.Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients:the FAVORIT trial[J]. Am J Transplant, 2012, 12(9):2437-2445.DOI: 10.1111/j.1600-6143.2012.04101.x.
    [11]
    LUCA L, WESTBROOK R, TSOCHATZIS EA.Metabolic and cardiovascular complications in the liver transplant recipient[J]. Ann Gastroenterol, 2015, 28(2):183-192. http://cn.bing.com/academic/profile?id=03b0c0c94e354cc633b9c25a7cc407ce&encoded=0&v=paper_preview&mkt=zh-cn
    [12]
    SAVIOLI G, SURBONE S, GIOVI I, et al.Early development of metabolic syndrome in patients subjected to lung transplantation[J]. Clin Transplant, 2013, 27(3):E237-E243.DOI: 10.1111/ctr.12098.
    [13]
    CARPENTER MA, JOHN A, WEIR MR, et al.BP, cardiovascular disease, and death in the folic acid for vascular outcome reduction in transplantation trial[J]. J Am Soc Nephrol, 2014, 25(7):1554-1562.DOI: 10.1681/ASN.2013040435.
    [14]
    MANGE KC, CIZMAN B, JOFFE M, et al.Arterial hypertension and renal allograft survival[J]. JAMA, 2000, 283(5):633-638. doi: 10.1001/jama.283.5.633
    [15]
    TEDLA FM, BRAR A, BROWNE R, et al.Hypertension in chronic kidney disease:navigating the evidence[J]. Int J Hypertens, 2011:132405.DOI: 10.4061/2011/132405.
    [16]
    OJO AO, HELD PJ, PORT FK, et al.Chronic renal failure after transplantation of a nonrenal organ[J]. N Engl J Med, 2003, 349(10):931-940. doi: 10.1056/NEJMoa021744
    [17]
    LUND LH, EDWARDS LB, KUCHERYAVAYA AY, et al.The Registry of the International Society for Heart and Lung Transplantation:thirty-second official adult heart transplantation report--2015;focus theme:early graft failure[J]. J Heart Lung Transplant, 2015, 34(10):1244-1254.DOI: 10.1016/j.healun.2015.08.003.
    [18]
    VECCHIATI A, TELLATIN S, ANGELINI A, et al.Coronary microvasculopathy in heart transplantation:consequences and therapeutic implications[J]. World J Transplant, 2014, 4(2):93-101.DOI: 10.5500/wjt.v4.i2.93.
    [19]
    陈伟伟, 高润霖, 刘力生, 等.《中国心血管病报告2014》概要[J].中国循环杂志, 2015, 30(7):617-622.DOI: 10.3969/j.issn.1000-3614.2015.07.001.

    CHEN WW, GAO RL, LIU LS, et al.Abstract of Chinese cardiovascular disease report 2014[J]. Chin Circul J, 2015, 30(7):617-622.DOI: 10.3969/j.issn.1000-3614.2015.07.001.
    [20]
    MAŁYSZKO J, MAŁYSZKO J, BACHÓRZEWSKA-GAJEWSKA H, et al.Inadequate blood pressure control in most kidney transplant recipients and patients with coronary artery disease with and without complications[J]. Transplant Proc, 2009, 41(8):3069-3072.DOI: 10.1016/j.transproceed.2009.07.078.
    [21]
    MARTÍNEZ-SALDIVAR B, PRIETO J, BERENGUER M, et al.Control of blood pressure in liver transplant recipients[J]. Transplantation, 2012, 93(10):1031-1037.DOI: 10.1097/TP.0b013e31824cd5e6.
    [22]
    WASILEWSKI G, PRZYBYLOWSKI P, JANIK L, et al.Inadequate blood pressure control in orthotopic heart transplant:is there a role of kidney function and immunosuppressive regimen?[J]. Transplant Proc, 2014, 46(8):2830-2834.DOI: 10.1016/j.transproceed.2014.09.034.
    [23]
    《中国高血压基层管理指南》修订委员会.中国高血压基层管理指南(2014年修订版)[J].中华健康管理学杂志, 2015, 9(1):10-30.DOI: 10.3760/cma.j.issn.1674-0815.2015.01.004.

    Committee for the Revision of Guidelines on Primary Hypertension Management in China.Guidelines on primary hypertension management in China (2014 revised edition)[J]. Chin J Health Manag, 2015, 9(1):10-30.DOI: 10.3760/cma.j.issn.1674-0815.2015.01.004.
    [24]
    2017 guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[EB/OL].[2018-07-10]. http://www.heart.org.
    [25]
    WILLIAMS B, MANCIA G, SPIERING W, et al.2018 ESC/ESH guidelines for the management of arterial hypertension[J]. Eur Heart J, 2018, 39(33):3021-3104.DOI: 10.1093/eurheartj/ehy339.
    [26]
    TALER SJ, AGARWAL R, BAKRIS GL, et al.KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD[J]. Am J Kidney Dis, 2013, 62(2):201-213.DOI: 10.1053/j.ajkd.2013.03.018.
    [27]
    CHATZIKYRKOU C, MENNE J, GWINNER W, et al.Pathogenesis and management of hypertension after kidney transplantation[J]. J Hypertens, 2011, 29(12):2283-2294.DOI: 10.1097/HJH.0b013e32834bd1e7.
    [28]
    FERNANDEZ FRESNEDO G, FRANCO ESTEVE A, GÓMEZ HUERTAS E, et al.Ambulatory blood pressure monitoring in kidney transplant patients:RETENAL study[J]. Transplant Proc, 2012, 44(9):2601-2602.DOI: 10.1016/j.transproceed.2012.09.037.
    [29]
    AHMED J, OZORIO V, FARRANT M, et al.Ambulatory vs office blood pressure monitoring in renal transplant recipients[J]. J Clin Hypertens (Greenwich), 2015, 17(1):46-50.DOI: 10.1111/jch.12448.
    [30]
    WADEI HM, AMER H, TALER SJ, et al.Diurnal blood pressure changes one year after kidney transplantation:relationship to allograft function, histology, and resistive index[J]. J Am Soc Nephrol, 2007, 18(5):1607-1615. doi: 10.1681/ASN.2006111289
    [31]
    HERMIDA RC, AYALA DE, FERNÁNDEZ JR, et al.Sleep-time blood pressure:prognostic value and relevance as a therapeutic target for cardiovascular risk reduction[J]. Chronobiol Int, 2013, 30(1/2):68-86.DOI: 10.3109/07420528.2012.702581.
    [32]
    RAMESH PRASAD GV.Ambulatory blood pressure monitoring in solid organ transplantation[J]. Clin Transplant, 2012, 26(2):185-191.DOI: 10.1111/j.1399-0012.2011.01569.x.
    [33]
    LAKKIS JI, WEIR MR.Treatment-resistant hypertension in the transplant recipient[J]. Semin Nephrol, 2014, 34(5):560-570.DOI: 10.1016/j.semnephrol.2014.08.010.
    [34]
    AMBROSI P, KREITMANN B, HABIB G.Home blood pressure monitoring in heart transplant recipients:comparison with ambulatory blood pressure monitoring[J]. Transplantation, 2014, 97(3):363-367.DOI: 10.1097/01.TP.0000435704.55805.f9.
    [35]
    HOORN EJ, WALSH SB, MCCORMICK JA, et al.The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension[J]. Nat Med, 2011, 17(10):1304-1309.DOI: 10.1038/nm.2497.
    [36]
    HESSELINK DA, BOUAMAR R, ELENS L, et al.The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation[J]. Clin Pharmacokinet, 2014, 53(2):123-139.DOI: 10.1007/s40262-013-0120-3.
    [37]
    HRICIK DE.Metabolic syndrome in kidney transplantation:management of risk factors[J]. Clin J Am Soc Nephrol, 2011, 6(7):1781-1785.DOI: 10.2215/CJN.01200211.
    [38]
    GHANTA M, KOZICKY M, JIM B.Pathophysiologic and treatment strategies for cardiovascular disease in end-stage renal disease and kidney transplantations[J]. Cardiol Rev, 2015, 23(3):109-118.DOI: 10.1097/CRD.0000000000000044.
    [39]
    HERNANDEZ VOTH AR, BENAVIDES MAÑAS PD, DE PABLO GAFAS A, et al.Sleep-related breathing disorders and lung transplantation[J]. Transplantation, 2015, 99(9):e127-e131.DOI: 10.1097/TP.0000000000000600.
    [40]
    GOICOECHEA M, GARCIA DE VINUESA S, VERDALLES U, et al.Allopurinol and progression of CKD and cardiovascular events:long-term follow-up of a randomized clinical trial[J]. Am J Kidney Dis, 2015, 65(4):543-549.DOI: 10.1053/j.ajkd.2014.11.016.
    [41]
    KIM ED, FAMURE O, LI Y, et al.Uric acid and the risk of graft failure in kidney transplant recipients:a re-assessment[J]. Am J Transplant, 2015, 15(2):482-488.DOI: 10.1111/ajt.13000.
    [42]
    GOIS PHF, SOUZA ERM.Pharmacotherapy for hyperuricemia in hypertensive patients[J]. Cochrane Database Syst Rev, 2017, 4:CD008652.DOI: 10.1002/14651858.CD008652.pub3.
    [43]
    SIKMA MA, VAN MAARSEVEEN EM, VAN DE GRAAF EA, et al.Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation[J]. Am J Transplant, 2015, 15(9):2301-2313.DOI: 10.1111/ajt.13309.
    [44]
    FIDALGO P, AHMED M, MEYER SR, et al.Incidence and outcomes of acute kidney injury following orthotopic lung transplantation:a population-based cohort study[J]. Nephrol Dial Transplant, 2014, 29(9):1702-1709.DOI: 10.1093/ndt/gfu226.
    [45]
    FIORETTO P, NAJAFIAN B, SUTHERLAND DE, et al.Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipients[J]. Clin J Am Soc Nephrol, 2011, 6(1):101-106.DOI: 10.2215/CJN.03850510.
    [46]
    WŁODARCZYK Z, GLYDA M, KOŚCIANSKA L, et al.Prevalence of arterial hypertension following kidney transplantationa multifactorial analysis[J]. Ann Transplant, 2003, 8(2):43-46. https://www.ncbi.nlm.nih.gov/pubmed/14626575
    [47]
    THOMAS B, TABER DJ, SRINIVAS TR.Hypertension after kidney transplantation:a pathophysiologic approach[J]. Curr Hypertens Rep, 2013, 15(5):458-469.DOI: 10.1007/s11906-013-0381-0.
    [48]
    PALANISAMY A, REEVES-DANIEL AM, FREEDMAN BI.The impact of APOL1, CAV1, and ABCB1 gene variants on outcomes in kidney transplantation:donor and recipient effects[J]. Pediatr Nephrol, 2014, 29(9):1485-1492.DOI: 10.1007/s00467-013-2531-7.
    [49]
    GRINYO JM, SAVAL N, CAMPISTOL JM, et al.Clinical assessment and determinants of chronic allograft nephropathy in maintenance renal transplant patients[J]. Nephrol Dial Transplant, 2011, 26(11):3750-3755.DOI: 10.1093/ndt/gfr091.
    [50]
    THOMAS B, WEIR MR.The evaluation and therapeutic management of hypertension in the transplant patient[J]. Curr Cardiol Rep, 2015, 17(11):95.DOI: 10.1007/s11886-015-0647-z.
    [51]
    RAO NN, COATES PT.Cardiovascular disease after kidney transplant[J]. Semin Nephrol, 2018, 38(3):291-297.DOI: 10.1016/j.semnephrol.2018.02.008.
    [52]
    WONG W, TOLKOFF-RUBIN N, DELMONICO FL, et al.Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction[J]. Clin Transplant, 2004, 18(4):341-348. doi: 10.1111/ctr.2004.18.issue-4
    [53]
    JOHNSON RW, KREIS H, OBERBAUER R, et al.Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure[J]. Transplantation, 2001, 72(5):777-786. doi: 10.1097/00007890-200109150-00007
    [54]
    KAMAR N, DEL BELLO A, BELLIERE J, et al.Calcineurininhibitor-sparing regimens based on mycophenolic acid after kidney transplantation[J]. Transpl Int, 2015, 28(8):928-937.DOI: 10.1111/tri.12515.
    [55]
    GILLIS KA, PATEL RK, JARDINE AG.Cardiovascular complications after transplantation:treatment options in solid organ recipients[J]. Transplant Rev (Orlando), 2014, 28(2):47-55.DOI: 10.1016/j.trre.2013.12.001.
    [56]
    DIEKMANN F.Immunosuppressive minimization with mTOR inhibitors and belatacept[J]. Transpl Int, 2015, 28(8):921-927.DOI: 10.1111/tri.12603.
    [57]
    GULLESTAD L, MORTENSEN SA, EISKJÆR H, et al.Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial[J]. Transplantation, 2010, 90(12):1581-1589.DOI: 10.1097/TP.0b013e3181fd01b7.
    [58]
    KNIGHT SR, MORRIS PJ.Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk.a Meta-analysis[J]. Transplantation, 2010, 89(1):1-14.DOI: 10.1097/TP.0b013e3181c518cc.
    [59]
    PHILIPP T, MARTINEZ F, GEIGER H, et al.Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients:results from SECRET[J]. Nephrol Dial Transplant, 2010, 25(3):967-976.DOI: 10.1093/ndt/gfp581.
    [60]
    IBRAHIM HN, JACKSON S, CONNAIRE J, et al.Angiotensin Ⅱ blockade in kidney transplant recipients[J]. J Am Soc Nephrol, 2013, 24(2):320-327.DOI: 10.1681/ASN.2012080777.
    [61]
    HIREMATH S, FERGUSSON D, DOUCETTE S, et al.Renin angiotensin system blockade in kidney transplantation:a systematic review of the evidence[J]. Am J Transplant, 2007, 7(10):2350-2360. doi: 10.1111/ajt.2007.7.issue-10
    [62]
    CROSS NB, WEBSTER AC, MASSON P, et al.Antihypertensive treatment for kidney transplant recipients[J]. Cochrane Database Syst Rev, 2009(3):CD003598.DOI: 10.1002/14651858.CD003598.pub2.
    [63]
    HEINZE G, MITTERBAUER C, REGELE H, et al.Angiotensin-converting enzyme inhibitor or angiotensin Ⅱtype 1 receptor antagonist therapy is associated withprolonged patient and graft survival after renal transplantation[J]. J Am Soc Nephrol, 2006, 17(3):889-899. doi: 10.1681/ASN.2005090955
    [64]
    OPELZ G, ZEIER M, LAUX G, et al.No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin Ⅱ type 1 receptor blockers:a collaborative transplant study report[J]. J Am Soc Nephrol, 2006, 17(11):3257-3262. doi: 10.1681/ASN.2006050543
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (233) PDF downloads(180) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return